Joseph M Unger1,2, Michael LeBlanc1,2, Charles D Blanke3. 1. SWOG Statistical Center, Seattle, Washington. 2. Fred Hutchinson Cancer Research Center, Seattle, Washington. 3. SWOG Group Chair's Office, Knight Cancer Institute, Oregon Health & Science University, Portland.
Abstract
IMPORTANCE: Recently, tremendous prominence has been given to the investigation of the effect of different research processes as part of the Cancer Moonshot. More than half a century ago, the National Cancer Institute (NCI) established a network of publicly funded cancer cooperative research groups to systematically evaluate new treatments for efficacy and safety. OBJECTIVE: To examine the extent to which positive NCI-sponsored cancer treatment trials have benefited patients with cancer in the US population. DESIGN, SETTING, AND PARTICIPANTS: This investigation used study data from SWOG, an NCI-sponsored network cooperative research group. All treatment trials during SWOG's 60-year history (1956-2016) were identified for which the new, experimental therapy provided a statistically significant improvement in overall survival. It was assumed that the new, proven treatments from these trials established new standards for cancer care in the treatment community. Twenty-three positive SWOG treatment trials were identified from a variety of different disease settings. MAIN OUTCOMES AND MEASURES: This study estimated population life-years gained from the 23 treatment trials through 2015 by mapping the effect of the new treatments onto the US cancer population using an area under the Kaplan-Meier survival curve approach that combined trial-specific hazard function and hazard ratio results, along with Surveillance, Epidemiology, and End Results program and life table data. Calculations were age adjusted. The US dollar return on investment was estimated as the ratio of the total investment by the NCI in the treatment trial program divided by the estimate of life-years gained. RESULTS: In total, 12 361 patients were enrolled to the 23 positive trials from 1965 to 2012. The study estimated that 3.34 million (95% confidence limit, 2.39-4.15 million) life-years were gained from these 23 trials through 2015. Estimates were greater than 2 million life-years gained under most model simulations. The US dollar return on investment was $125 per life-year gained. CONCLUSIONS AND RELEVANCE: SWOG treatment trials have had a substantial impact on population survival for patients with cancer over 60 years. The NCI's investment in its cancer cooperative group research program has provided exceptional value and benefit to the American public through its research programs generating positive cancer treatment trials. TRIAL REGISTRATION: clinicaltrials.gov Identifiers: NCT00004001, NCT00075764, and NCT00644228.
IMPORTANCE: Recently, tremendous prominence has been given to the investigation of the effect of different research processes as part of the Cancer Moonshot. More than half a century ago, the National Cancer Institute (NCI) established a network of publicly funded cancer cooperative research groups to systematically evaluate new treatments for efficacy and safety. OBJECTIVE: To examine the extent to which positive NCI-sponsored cancer treatment trials have benefited patients with cancer in the US population. DESIGN, SETTING, AND PARTICIPANTS: This investigation used study data from SWOG, an NCI-sponsored network cooperative research group. All treatment trials during SWOG's 60-year history (1956-2016) were identified for which the new, experimental therapy provided a statistically significant improvement in overall survival. It was assumed that the new, proven treatments from these trials established new standards for cancer care in the treatment community. Twenty-three positive SWOG treatment trials were identified from a variety of different disease settings. MAIN OUTCOMES AND MEASURES: This study estimated population life-years gained from the 23 treatment trials through 2015 by mapping the effect of the new treatments onto the US cancer population using an area under the Kaplan-Meier survival curve approach that combined trial-specific hazard function and hazard ratio results, along with Surveillance, Epidemiology, and End Results program and life table data. Calculations were age adjusted. The US dollar return on investment was estimated as the ratio of the total investment by the NCI in the treatment trial program divided by the estimate of life-years gained. RESULTS: In total, 12 361 patients were enrolled to the 23 positive trials from 1965 to 2012. The study estimated that 3.34 million (95% confidence limit, 2.39-4.15 million) life-years were gained from these 23 trials through 2015. Estimates were greater than 2 million life-years gained under most model simulations. The US dollar return on investment was $125 per life-year gained. CONCLUSIONS AND RELEVANCE: SWOG treatment trials have had a substantial impact on population survival for patients with cancer over 60 years. The NCI's investment in its cancer cooperative group research program has provided exceptional value and benefit to the American public through its research programs generating positive cancer treatment trials. TRIAL REGISTRATION: clinicaltrials.gov Identifiers: NCT00004001, NCT00075764, and NCT00644228.
Authors: R C Flanigan; S E Salmon; B A Blumenstein; S I Bearman; V Roy; P C McGrath; J R Caton; N Munshi; E D Crawford Journal: N Engl J Med Date: 2001-12-06 Impact factor: 91.245
Authors: Laura F Hutchins; Stephanie J Green; Peter M Ravdin; Danika Lew; Silvana Martino; Martin Abeloff; Alan P Lyss; Craig Allred; Saul E Rivkin; C Kent Osborne Journal: J Clin Oncol Date: 2005-11-20 Impact factor: 44.544
Authors: D S Alberts; P Y Liu; E V Hannigan; R O'Toole; S D Williams; J A Young; E W Franklin; D L Clarke-Pearson; V K Malviya; B DuBeshter Journal: N Engl J Med Date: 1996-12-26 Impact factor: 91.245
Authors: W A Peters; P Y Liu; R J Barrett; R J Stock; B J Monk; J S Berek; L Souhami; P Grigsby; W Gordon; D S Alberts Journal: J Clin Oncol Date: 2000-04 Impact factor: 44.544
Authors: H Glucksberg; S E Rivkin; S Rasmussen; B Tranum; N Gad-el-Mawla; J Costanzi; B Hoogstraten; J Athens; T Maloney; J McCracken; C Vaughn Journal: Cancer Date: 1982-08-01 Impact factor: 6.860
Authors: A J Wozniak; J J Crowley; S P Balcerzak; G R Weiss; C H Spiridonidis; L H Baker; K S Albain; K Kelly; S A Taylor; D R Gandara; R B Livingston Journal: J Clin Oncol Date: 1998-07 Impact factor: 44.544
Authors: Rita S Mehta; William E Barlow; Kathy S Albain; Ted A Vandenberg; Shaker R Dakhil; Nagendra R Tirumali; Danika L Lew; Daniel F Hayes; Julie R Gralow; Robert B Livingston; Gabriel N Hortobagyi Journal: N Engl J Med Date: 2012-08-02 Impact factor: 91.245
Authors: Monica M Bertagnolli; Susan M Blaney; Charles D Blanke; Walter J Curran; Janet Dancey; Robert S Mannel; Peter J O'Dwyer; Mitchell D Schnall; Norman Wolmark Journal: J Natl Cancer Inst Date: 2019-01-01 Impact factor: 13.506
Authors: Samilia Obeng-Gyasi; Sheetal M Kircher; Kelsey P Lipking; Benjamin J Keele; Al B Benson; Lynne I Wagner; Ruth C Carlos Journal: Cancer Date: 2019-06-28 Impact factor: 6.860
Authors: Cristina Merkhofer; Shasank Chennupati; Qin Sun; Keith D Eaton; Renato G Martins; Scott D Ramsey; Bernardo H L Goulart Journal: JCO Oncol Pract Date: 2021-08
Authors: Joseph M Unger; Charles D Blanke; Michael LeBlanc; William E Barlow; Riha Vaidya; Scott D Ramsey; Dawn L Hershman Journal: JAMA Netw Open Date: 2020-04-01
Authors: Gwendolyn Ho; Ted Wun; Lori Muffly; Qian Li; Ann Brunson; Aaron S Rosenberg; Brian A Jonas; Theresa H M Keegan Journal: Cancer Date: 2018-02-16 Impact factor: 6.921